Kura Oncology Statistics
Total Valuation
Kura Oncology has a market cap or net worth of $942.98 million. The enterprise value is $448.41 million.
| Market Cap | 942.98M |
| Enterprise Value | 448.41M |
Important Dates
The next estimated earnings date is Tuesday, November 3, 2026, before market open.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Kura Oncology has 88.96 million shares outstanding. The number of shares has increased by 1.16% in one year.
| Current Share Class | 88.96M |
| Shares Outstanding | 88.96M |
| Shares Change (YoY) | +1.16% |
| Shares Change (QoQ) | +0.28% |
| Owned by Insiders (%) | 1.59% |
| Owned by Institutions (%) | 80.39% |
| Float | 70.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.21 |
| Forward PS | 6.43 |
| PB Ratio | 19.47 |
| P/TBV Ratio | 19.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.73, with a Debt / Equity ratio of 0.50.
| Current Ratio | 4.73 |
| Quick Ratio | 4.50 |
| Debt / Equity | 0.50 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -224.01 |
Financial Efficiency
Return on equity (ROE) is -167.71% and return on invested capital (ROIC) is -99.94%.
| Return on Equity (ROE) | -167.71% |
| Return on Assets (ROA) | -31.30% |
| Return on Invested Capital (ROIC) | -99.94% |
| Return on Capital Employed (ROCE) | -67.74% |
| Weighted Average Cost of Capital (WACC) | 6.77% |
| Revenue Per Employee | $297,019 |
| Profits Per Employee | -$1.14M |
| Employee Count | 260 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Kura Oncology has paid $84,000 in taxes.
| Income Tax | 84,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +5.16% in the last 52 weeks. The beta is 0.47, so Kura Oncology's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | +5.16% |
| 50-Day Moving Average | 11.27 |
| 200-Day Moving Average | 9.81 |
| Relative Strength Index (RSI) | 40.31 |
| Average Volume (20 Days) | 1,760,259 |
Short Selling Information
The latest short interest is 14.82 million, so 16.66% of the outstanding shares have been sold short.
| Short Interest | 14.82M |
| Short Previous Month | 13.42M |
| Short % of Shares Out | 16.66% |
| Short % of Float | 21.01% |
| Short Ratio (days to cover) | 6.42 |
Income Statement
In the last 12 months, Kura Oncology had revenue of $77.23 million and -$296.78 million in losses. Loss per share was -$3.36.
| Revenue | 77.23M |
| Gross Profit | -182.81M |
| Operating Income | -318.09M |
| Pretax Income | -296.69M |
| Net Income | -296.78M |
| EBITDA | -316.80M |
| EBIT | -318.09M |
| Loss Per Share | -$3.36 |
Balance Sheet
The company has $519.03 million in cash and $24.46 million in debt, with a net cash position of $494.57 million or $5.56 per share.
| Cash & Cash Equivalents | 519.03M |
| Total Debt | 24.46M |
| Net Cash | 494.57M |
| Net Cash Per Share | $5.56 |
| Equity (Book Value) | 48.43M |
| Book Value Per Share | 0.54 |
| Working Capital | 441.25M |
Cash Flow
In the last 12 months, operating cash flow was -$111.76 million and capital expenditures -$5.67 million, giving a free cash flow of -$117.43 million.
| Operating Cash Flow | -111.76M |
| Capital Expenditures | -5.67M |
| Depreciation & Amortization | 1.29M |
| Net Borrowing | n/a |
| Free Cash Flow | -117.43M |
| FCF Per Share | -$1.32 |
Margins
| Gross Margin | -236.72% |
| Operating Margin | -411.90% |
| Pretax Margin | -384.19% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Kura Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.16% |
| Shareholder Yield | -1.16% |
| Earnings Yield | -31.47% |
| FCF Yield | -12.45% |
Analyst Forecast
The average price target for Kura Oncology is $31.85, which is 200.47% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $31.85 |
| Price Target Difference | 200.47% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (3Y) | 61.34% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Kura Oncology has an Altman Z-Score of -3.02 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.02 |
| Piotroski F-Score | 2 |